CircHAS2 activates CCNE2 to promote cell proliferation and sensitizes the response of colorectal cancer to anlotinib

• Published in: Molecular cancer Vol. 23; no. 1; pp. 59 - 19
• Main Authors: Li, Haosheng, Feng, Haoran, Zhang, Tao, Wu, Junwei, Shen, Xiaonan, Xu, Shuiyu, Xu, Lianghui, Wang, Shaodong, Zhang, Yaqi, Jia, Wenqing, Ji, Xiaopin, Cheng, Xi, Zhao, Ren
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.03.2024; BioMed Central; BMC
• Subjects: Angiogenesis; Anlotinib; Antibodies; Biomarker; Biomarkers; Cancer; Cancer therapies; Care and treatment; Cell culture; Cell cycle; Cell growth; Cell proliferation; Chemotherapy; circRNAs; Circular RNA; Clinical trials; Colorectal cancer; Colorectal carcinoma; Drugs; Ethics; Health aspects; Hybridization; Kinases; Medical colleges; Medical research; Medicine, Experimental; Metastasis; Molecular biology; Molecular modelling; Mortality; Nuclear transport; Organoids; Patients; Plasmids; Proteins; RNA sequencing; Transcriptomes; Translation; Tumor proteins; Tumors; Tyrosine kinase inhibitors; Xenografts; China; United States > US; circRNAs; Anlotinib; Biomarker; Translation; Colorectal cancer

Tyrosine kinase inhibitors (TKIs) are crucial in the targeted treatment of advanced colorectal cancer (CRC). Anlotinib, a multi-target TKI, has previously been demonstrated to offer therapeutic benefits in previous studies. Circular RNAs (circRNAs) have been implicated in CRC progression and their u...